eNeura Therapeutics

eNeura operates in the migraine-treatment segment of medical devices, focusing on non-invasive neuromodulation rather than conventional pharmaceutical therapy. Its differentiation is the combination of single-pulse transcranial magnetic stimulation, prescription-based distribution, and patient-administered treatment at home or while traveling. The company’s SAVI Dual Migraine Therapy is described as supporting both acute and preventive care, while sTMS and sTMS mini extend the platform across U.S. and U.K. prescription settings. Relevant competitive alternatives include Cefaly, which uses external trigeminal nerve stimulation; Nerivio, a remote electrical neuromodulation device; and gammaCore, a non-invasive vagus nerve stimulation system. Compared with those approaches, eNeura’s stated distinction is magnetic stimulation delivered through portable devices, including treatment sessions designed to take less than a minute. The company’s $75.8 million funding base indicates substantial historical capital investment, although its last recorded financing was in 2019.

eNeura’s trajectory reflects a long medical-device development cycle supported by repeated financing between 2012 and 2019. The company raised $1 million in a November 2012 Venture Round, followed by additional venture and debt financings, including $15 million in debt in March 2015, $6.39 million in March 2016, and a $17 million Series D in February 2018. A further $5.91 million debt financing on November 4, 2019 brought cumulative funding to $75.79 million across 14 rounds. Product development has progressed from the broader sTMS platform to named offerings including sTMS mini and SAVI Dual Migraine Therapy, with the latter targeting both acute and preventive migraine treatment for patients aged 12 and older. The company reports a current employee band of 11 to 50 people and lists three featured current positions, suggesting a relatively focused operating structure rather than rapid headcount expansion. Its website also highlights a cloud-based smart diary and personalized clinical support, indicating an effort to pair hardware with patient-engagement infrastructure.